We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+7.64%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.56B
AUM Growth
+$19.4M
Cap. Flow
-$249M
Cap. Flow %
-3.79%
Top 10 Hldgs %
37.22%
Holding
183
New
22
Increased
65
Reduced
79
Closed
14

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$38.5M
2
SAGE
Sage Therapeutics
SAGE
+$22M
3
SIBN icon
SI-BONE Inc
SIBN
+$19.1M
4
STE icon
Steris
STE
+$16.6M
5
CLDX icon
Celldex Therapeutics
CLDX
+$15.6M

Top Sells

Rank Stock Value
1
AXNX
Axonics, Inc. Common Stock
AXNX
+$114M
2
ISRG icon
Intuitive Surgical
ISRG
+$56.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$51.2M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$28.6M
5
EVH icon
Evolent Health
EVH
+$28.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.12%
2 Industrials 0.77%
3 Technology 0.02%
4 Communication Services 0.02%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENE icon
126
Xenon Pharmaceuticals
XENE
$6.38B
$607K 0.01%
14,100
-7,900
-36% -$363K
PTGX icon
127
Protagonist Therapeutics
PTGX
$8.64B
$554K 0.01%
19,146
-10,854
-36% -$295K
RYTM icon
128
Rhythm Pharmaceuticals
RYTM
$7.17B
$542K 0.01%
12,500
-20,369
-62% -$891K
RCKT icon
129
Rocket Pharmaceuticals
RCKT
$375M
$531K 0.01%
19,700
-1,300
-6% -$36.9K
FDMT icon
130
4D Molecular Therapeutics
FDMT
$580M
$500K 0.01%
+15,700
New +$401K
BPMC
131
DELISTED
Blueprint Medicines
BPMC
$484K 0.01%
+5,100
New +$437K
CCCC icon
132
C4 Therapeutics
CCCC
$396M
$471K 0.01%
57,600
-4,400
-7% -$34.1K
THC icon
133
Tenet Healthcare
THC
$16.7B
$446K 0.01%
4,244
+2,797
+193% +$251K
VKTX icon
134
Viking Therapeutics
VKTX
$4.22B
$443K 0.01%
5,400
-12,100
-69% -$538K
MRUS
135
DELISTED
Merus
MRUS
$441K 0.01%
9,800
-12,900
-57% -$523K
ASTH icon
136
Astrana Health
ASTH
$2.21B
$431K 0.01%
+10,256
New +$400K
GRMN
137
Garmin
GRMN
$47.2B
$417K 0.01%
+2,800
New +$369K
BBIO icon
138
BridgeBio Pharma
BBIO
$15.8B
$396K 0.01%
12,800
-20,500
-62% -$697K
VERV
139
DELISTED
Verve Therapeutics
VERV
$388K 0.01%
29,200
-9,800
-25% -$130K
AAPL icon
140
Apple
AAPL
$4.8T
$377K 0.01%
+2,200
New +$400K
WST icon
141
West Pharmaceutical
WST
$24.9B
$344K 0.01%
+870
New +$322K
DVAX
142
DELISTED
Dynavax Technologies
DVAX
$342K 0.01%
27,558
-15,642
-36% -$204K
CAH icon
143
Cardinal Health
CAH
$52.9B
$336K 0.01%
3,000
-500
-14% -$53.9K
VRDN icon
144
Viridian Therapeutics
VRDN
$2.05B
$334K 0.01%
19,100
-10,900
-36% -$211K
BCYC
145
Bicycle Therapeutics
BCYC
$290M
$311K ﹤0.01%
12,500
-7,500
-38% -$159K
MDGL icon
146
Madrigal Pharmaceuticals
MDGL
$12.4B
$283K ﹤0.01%
+1,060
New +$250K
AMRX icon
147
Amneal Pharmaceuticals
AMRX
$5.59B
$275K ﹤0.01%
45,387
+19,917
+78% +$112K
ADMA icon
148
ADMA Biologics
ADMA
$2.03B
$270K ﹤0.01%
+40,900
New +$224K
SMPL icon
149
Simply Good Foods
SMPL
$966M
$269K ﹤0.01%
+7,900
New +$291K
BMEA icon
150
Biomea Fusion
BMEA
$94.7M
$266K ﹤0.01%
17,800
-7,200
-29% -$119K
4 5
6
7 8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2024 Portfolio in Review

As of Q1 2024, Bellevue Group held 183 positions worth $6.56B, up 0.3% from $6.54B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Bellevue Group withdrew a net $249M in Q1 2024, closing 14 positions and reducing 79 holdings. Its most notable exit was Axonics, Inc. Common Stock, an estimated $114M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Industrials and Technology.

Against the trend, Bellevue Group opened a new position in Steris worth $16.5M.

  • Bellevue Group's largest Q1 2024 buy was Steris: 73,434 shares worth $16.5M.
  • Bellevue Group added most to DexCom in Q1 2024, an estimated $38.5M increase.
  • Bellevue Group's biggest Q1 2024 reduction was Intuitive Surgical, cutting an estimated $56.6M.
  • Bellevue Group fully exited Axonics, Inc. Common Stock in Q1 2024, selling an estimated $114M.
  • Bellevue Group's ten largest holdings make up 37% of its $6.56B portfolio in Q1 2024.
  • Bellevue Group opened 22 new positions and closed 14 in Q1 2024.
  • Bellevue Group's portfolio value rose 0.3% quarter-over-quarter to $6.56B.

Based on Bellevue Group's 13F filing for Q1 2024, filed 15 May 2024.